Back

Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center

Rimland, C. A.; Morgan, C. E.; Bell, G. J.; Kim, M. K.; Hedrick, T.; Marx, A.; Bramson, B.; Swygard, H.; Napravnik, S.; Schmitz, J. L.; Carson, S. S.; Fischer, W. A.; Eron, J. J.; Gay, C. L.; Parr, J. B.

2020-06-13 infectious diseases
10.1101/2020.05.13.20100404 medRxiv
Show abstract

We describe early outcomes in 11 COVID-19 patients treated with the IL-6 receptor inhibitor tocilizumab. While C-reactive protein decreased, neither clinical improvement nor reduced temperature or oxygen requirements was observed in most patients. Our findings contrast with prior reports and raise questions about tocilizumab use in severe COVID-19.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.